|Videos|February 4, 2021
Tarsus execs discuss origins, treating Demodex blepharitis
Author(s)OT Staff Reports
Tarsus Pharmaceuticals's CEO Bobby Azamian, MD, PhD, and Chairman Michael Ackermann, PhD, speak on the development of their company and the latest updates on their lead candidate product to treat Demodex blepharitis.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Idebenone accepted by FDA for priority review for Leber Hereditary Optic Neuropathy
2
Luxa Biotechnology announces clinical trial results for treatment of AMD
3
STAAR Surgical confirms expiration of “window shop” period in Alcon merger agreement
4
The European Commission grants marketing authorization for EYLUXVI
5